Clinical Trial Update: Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial evaluating golcadomide, poseltinib, and rituximab for relapsed/refractory diffuse large B-cell lymphoma, with recruitment not y…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Golcadomide (golcadomide)
• POSELTINIB (POSELTINIB)
• Rituximab (rituximab)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Large B-Cell Lymphoma (LBCL) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING